Analgesic Efficacy of Controlled‐Release Oxycodone in Postoperative Pain

  title={Analgesic Efficacy of Controlled‐Release Oxycodone in Postoperative Pain},
  author={Abraham Sunshine and Nancy Z. Olson and A. Colon and Juana Rivera and Robert Francis Kaiko and Ronald D. Fitzmartin and Robert F. Reder and Paul D. Goldenheim},
  journal={The Journal of Clinical Pharmacology},
The efficacy and safety of graded doses (10, 20, and 30 mg) of controlled‐release (CR) oxycodone was compared with that of immediate‐release (IR) oxycodone (15 mg), immediate‐release oxycodone 10 mg in combination with acetaminophen 650 mg (APAP), and placebo in a single‐dose, double‐blind, randomized, parallel‐group study. The participants, 182 inpatients experiencing moderate to severe pain after abdominal or gynecologic surgery, provided hourly ratings of pain intensity and relief for 12… 
Controlled-release oxycodone and morphine in cancer related pain
Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain.
  • R. Kaplan, W. Parris, R. Kaiko
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
CR oxycodone every 12 hours was as effective as IR oxyCodone four times daily in managing moderate to severe cancer-related pain and was associated with fewer reports of adverse events.
Randomized, Double‐Blind, Placebo‐Controlled Comparison of the Analgesic Efficacy of Oxycodone 10 mg/Acetaminophen 325 mg versus Controlled‐Release Oxycodone 20 mg in Postsurgical Pain
Combination agent was statistically superior to CR oxycodone in four of five outcome measures of pain intensity and pain relief and provided a faster onset and 24% reduction in the number of patients reporting treatment‐related adverse events compared with twice the dose of opioid alone.
Clinical efficacy of OxyContin in the treatment of cancer pain
OxyContin was effective in the treatment of moderate to severe cancer pain, with rapid onset, good analgesic performance, mild adverse effect and safety profile.
Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement.
CR oxycodone every 12 hours is as effective as ST in treating postoperative pain but length of hospital stay was shorter and analgesic administration in the hospital was used less frequently, providing potential hospital cost savings and reduced use of health care resources.
Efficacy and Tolerability of Oxycodone Hydrochloride Controlled-Release Tablets in Moderate to Severe Cancer Pain
OCRT is well tolerated and effective in controlling moderate to severe cancer pain in Chinese patients and scores on all six QOL items increased significantly compared with baseline but showed varying rates of improvement.
Clinical Equivalence of Controlled-Release Oxycodone 20 mg and Controlled-Release Tramadol 200 mg after Surgery for Breast Cancer
Assessment of clinical equivalence of 20 mg controlled-release oxycodone and 200 mgcontrolled-release tramadol on a 12-hour dosing schedule in a randomized, double-blinded study of 54 ASA I–III physical status patients undergoing surgery for breast cancer found it clinically equivalent.
Double‐Blind, Randomized Comparison of the Analgesic and Pharmacokinetic Profiles of Controlled‐ and Immediate‐Release Oral Oxycodone in Cancer Pain Patients
Following repeat dosing under double‐blind conditions, oral CR oxycodone administered q12h provided analgesia comparable to IR oxy codone given qid, and acceptance of therapy and pain scores correlated with plasma oxyCodone concentrations for each interval and were similar for both medications.
Prolonged-release Oxycodone/Naloxone in Postoperative Pain Management: From a Randomized Clinical Trial to Usual Clinical Practice
The analgesic efficacies of OXN PR and OXY PR were similar in postoperative pain settings and reduced the degree of restriction in relation to patients carrying out physio - therapy compared with other opioids, and improved bowel and bladder function.


Dose-ranging study of oxycodone for chronic pain in advanced cancer.
  • P. Glare, T. Walsh
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
Oxycodone has been shown for the first time to be as versatile and flexible as oral morphine in the management of chronic pain in patients with advanced cancer.
Morphine and oxycodone hydrochloride in the management of cancer pain
In a double‐blind crossover study, morphine and oxycodone hydrochloride were administered to 20 patients who were experiencing severe cancer pain and there were no major differences in the side effects between these two opioids.
Diclofenac and oxycodone in treatment of postoperative pain: a double‐blind trial
Diclofenac is an alternative to opiates in the management of postoperative pain, especially useful in patients in whom opiates cause side‐effects.
Intravenous morphine and oxycodone for pain after abdominal surgery
The “first state of pain relief” was achieved faster and lasted longer with oxycodone than morphine and in other respects the two opioids were comparable.
Controlled Comparison of the Efficacy of Fourteen Preparations in the Relief of Postoperative Pain
Thirteen analgesic drugs, four of them at two dose levels, four analgesics in combination with antagonist or neuroleptic agents, and saline have been evaluated simultaneously in the relief of
Single‐dose and steady‐state pharmacokinetics and pharmacodynamics of oxycodone in patients with cancer
The marked interindividual variation observed in the pharmacokinetics and pharmacodynamics of oxycodone in this study supports the need for individualized dosing regimens.
A review of oxycodone's clinical pharmacokinetics and pharmacodynamics.
Comparison of i.m. lysine acetylsalicylate and oxycodone in the treatment of pain after operation.
No significant differences were found between the smaller and larger doses of LAS, suggesting a plateau effect, and further clinical experiments with LAS using i.v. mode of administration and other pain models are warranted.
Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine.
The results of these studies do not appear to support the hypothesis that, in man, the analgesic activity of codeine is due to its O-demethylation to morphine, and demonstrate a highly consistent pattern of analgesic structure-activity relationships encompassing morphine, oxymorphone, codeine and oxycodone.